^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Peritoneal Cancer

    3d
    Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Columbia University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    cisplatin
    3d
    Malignant transformation of a testosterone-secreting ovarian steroid cell tumor: a case report. (PubMed, Gynecol Oncol Rep)
    Despite adjuvant carboplatin, paclitaxel, and bevacizumab followed by maintenance therapy, she developed platinum-resistant progression with peritoneal and nodal disease and is currently receiving additional systemic therapy with poor response. This case highlights the potential for malignant transformation in benign-appearing SCT-NOS and underscores the importance of counseling patients on the rare risk of recurrence and the need for novel therapeutic strategies in recurrent disease. Integration of clinical, pathologic, and molecular data may improve risk stratification and management of this rare tumor.
    Journal
    |
    STK11 (Serine/threonine kinase 11) • LZTR1 (Leucine Zipper Like Transcription Regulator 1)
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel
    4d
    R4018-ONC-1721: Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (clinicaltrials.gov)
    P1/2, N=890, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jan 2027 --> May 2027 | Trial primary completion date: Feb 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Libtayo (cemiplimab-rwlc) • Actemra IV (tocilizumab) • ubamatamab (REGN4018) • Kevzara (sarilumab)
    5d
    PROTA: Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. (clinicaltrials.gov)
    P1/2, N=29, Active, not recruiting, TILT Biotherapeutics Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • Platinum resistant
    |
    Keytruda (pembrolizumab) • pegylated liposomal doxorubicin • igrelimogene litadenorepvec (TILT-123)
    5d
    Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) (clinicaltrials.gov)
    P2/3, N=175, Recruiting, GE Healthcare | Not yet recruiting --> Recruiting
    Enrollment open
    5d
    Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis (clinicaltrials.gov)
    P2, N=12, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Scientific reprioritization. Closed per principal investigator discretion to prioritize enrollment in another study.
    Trial termination
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    paclitaxel • capecitabine
    5d
    Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma. (PubMed, Clin Transl Med)
    Retroperitoneal sarcoma cells can secrete prolactin into the bloodstream, inducing hyperprolactinaemia, which subsequently triggers metabolic reprogramming, such as glucose metabolism. SOX4 can function as a transcription factor that facilitates PRL transcription. PRL can activate the JAK-STAT signalling pathway by binding to PRLR on sarcoma cells, leading to the up-regulation of c-MYC.
    Journal
    |
    YBX1 (Y-Box Binding Protein 1) • PRLR (Prolactin Receptor 2) • PRL (Prolactin) • SOX4 (SRY-Box Transcription Factor 4) • TCF4 (Transcription Factor 4)
    6d
    Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study) (clinicaltrials.gov)
    P=N/A, N=30, Suspended, Rutgers, The State University of New Jersey | Trial completion date: Nov 2024 --> Sep 2027 | Recruiting --> Suspended | Trial primary completion date: Nov 2024 --> Jun 2027
    Trial completion date • Trial suspension • Trial primary completion date • Circulating tumor DNA
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Signatera™
    6d
    MRD: Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Imunon | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial primary completion date
    |
    carboplatin • paclitaxel • IMNN-001
    9d
    NRG-GY009: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2/3, N=444, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Apr 2027
    Trial completion date • Platinum resistant
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • pegylated liposomal doxorubicin • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    10d
    Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=155, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Mar 2027
    Trial completion date
    |
    BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    10d
    Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Mar 2027
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)